Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis

Conference Reports for NATAP

EASL 2024
June 5-8, Milan, Italy


Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis

	EASL 2024 June 5-8 Milan Italy Elisabetta Degasperi (Milan, Italy)